Oral treatment of inflammatory bowel disease
US9217021B2 · kind B2 · utility
1Cited by
7References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 5, 2012 |
| Grant date | Dec 22, 2015 |
| Priority date | — |
| Expiry date | Jul 5, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/4723
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Treatment of an inflammatory bowel disease in a subject in need thereof by simultaneous or successive parenteral and oral administration of a mammalian beta defensin is described. Oral administration of mammalian beta defensin to a subject during remission to keep said subject suffering from IBD in remission, prolong remission in said subject suffering from IBD, to reduce the occurrence of relapse in said subject suffering from IBD, or any combination thereof, is also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.